Garry Arthur Neil, Chief Scientific Officer at Avalo Therapeutics, Inc. (AVTX), bought 4,267 shares at $1.57 ($7K) on 2021-12-10, disclosed to the SEC on 2021-12-14.
Open-market purchase of $7k AVTX by Chief Scientific Officer. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Something here stands out, but not much.
| Filing → |
| CERC | BUY | 2021-06-14 | $8K | — | Filing → |
| CERC | BUY | 2020-12-14 | $8K | — | Filing → |
| CERC | BUY | 2020-06-11 | $4K | — | Filing → |